fashion -WSS

fashion

author：focus 2025-09-30 22:04:21 - browse：48

Adam's take main illustration — Molly Ferguson/STAT

The Food and Drug Administration should halt Cassava Sciences’ ongoing clinical trials in Alzheimer’s disease. That, and other thoughts on the fallout from the City University of New York investigation that raised serious doubts about the science underpinning the company’s experimental drug simufilam.

Patient safety is paramount to the FDA, so stopping Cassava’s two Phase 3 studies is the ethically correct thing to do.The FDA has the power to place clinical holds on experimental drugs when there’s evidence of an unacceptable safety risk to study participants. Simufilam doesn’t appear to be toxic. It’s not causing dangerous side effects. But study participants can also be harmed when they volunteer for a clinical trial based on false or misleading information about a drug’s potential efficacy.

The CUNY committee charged with investigating Cassava’s principal scientific collaborator, the neuroscientist Hoau-Yan Wang, could not definitively prove that Wang faked simufilam data, but that’s only because he refused to turn over original data and primary research records that the committee had requested to examine. Wang also claimed that boxes of research records relevant to the investigation were thrown away. The investigative report was first made public last week in the journal Science.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Why depression after traumatic brain injury is distinct

leisure time

WSS

First U.S. drug developed to treat liver disease MASH is approved

President Biden's budget: Here's what you might have missed

Physician groups backed by private equity giant lobby on mergers

Readout Newsletter: CAR

Amazon expands telehealth clinic nationwide

First U.S. drug developed to treat liver disease MASH is approved

entertainment

fashion

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

What the US credit downgrade means for the economy, your finances

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

After affirmative action ruling, medical educators look to 'holistic review'

President Biden's budget: Here's what you might have missed

Wildfire smoke exposes gaps in outdoor worker protections

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

First U.S. drug developed to treat liver disease MASH is approved

entertainment

Pushing for an NIH office for post

Ebola: Gilead Sciences antiviral shows promise as new treatment

What to expect as Trump is arraigned on his Jan 6. indictment

Steward Health Care Massachusetts hospitals face fiscal disaster

Medicare coverage of Wegovy, once blocked, now looks possible

Male and female sex labels in research insufficient, scientists say

leisure time

focus

hotspot

focus